Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Market Alert: New Report Highlights Steakholder Foods Major Shift to Commercialization & Revenue Generation

Global Markets News

A new report by PESG Research highlights Steakholder Foods’ (NASDAQ: STKH) transformative journey from research and development to commercialization in the alternative protein and 3D food printing sectors. The report highlights how 2024 marked a pivotal year for the company, with strategic partnerships fueling revenue generation and positioning Steakholder Foods for potential growth in a booming market. Strategic Partnerships Lay Foundation for Revenue Growth Steakholder Foods secured multiple strategic agreements in 2024 that validate its proprietary technology and solidify its commercial potential. Key partnerships include a commercial memorandum of understanding with Wyler Farm, which involves the purchase of Steakholder Foods’ MX200 meat printer and SH™-Beef premix blends. This agreement also encompasses royalties and raw materials supply, enabling large-scale production of alternative proteins. Additional partnerships with the Industrial Technology Research Institute (ITRI) in Taiwan and regional collaborations in the Gulf Cooperation Council (GCC) highlight the company’s international reach. The GCC partnership, aimed at supporting local food security initiatives, involves constructing a pilot facility for hybrid-cultivated fish production and showcases Steakholder Foods’ scalability in new markets. These agreements are seen as significant steps toward establishing long-term, recurring revenue streams. Initial Purchase Orders Signal Commercial Viability According to the company, initial purchase orders from key partners such as Bondor Foods and Wyler Farm have initiated revenue streams, providing critical proof of concept for Steakholder Foods’ business model. In September 2024, Bondor Foods placed its first order for plant-based premixes for white fish and salmon patties, followed by Wyler Farm’s order for SH™-Beef premix for a new line of plant-based meat products. These initial revenues underscore the company’s successful transition from R&D to commercialization. Moreover, in a bid to attract new clients and partners, Steakholder Foods inaugurated a state-of-the-art Demonstration Center in Israel. The facility showcases live demonstrations of its MX200 and HD144 3D printers, highlighting their capabilities in real-time production of plant-based meat and seafood alternatives. This hands-on experience allows potential partners to witness the full production process, reinforcing the quality and versatility of Steakholder Foods’ offerings. Positioned for Potential Growth in Expanding Markets The PESG report places Steakholder Foods within the context of a rapidly expanding alternative protein market, projected to grow from $76.3 billion in 2023 to $423 billion by 2033. This growth is driven by consumer interest in sustainable and health-conscious food options. Additionally, the 3D food printing market is expected to surge, with estimates forecasting growth from USD 34.7 million in 2019 to USD 1,015.4 million by 2027, driven by advances in technology and consumer demand for innovative food solutions. The report highlights how Steakholder Foods’ advancements potentially align with these industry trends, positioning the company as a potential leader in sustainable food production. Its proprietary 3D printing technology and strategic partnerships are poised to capture a share of this growing demand, particularly as cost management initiatives and recurring revenues take effect. Outlook and Future Prospects With strategic partnerships maturing and a demonstration center enhancing its market presence, Steakholder Foods appears poised for potential revenue growth in the coming years. The company has noted that it is in advanced discussions for a high-impact international agreement expected to close by early 2025. This move could further bolster Steakholder Foods’ position as a leader in the alternative protein sector, which continues to gain momentum amid shifting consumer preferences and sustainability goals. Read the Full PESG Report: https://finance.yahoo.com/news/pesg-research-report-steakholder-foods-134500909.html *Please refer to the report’s full disclaimers and disclosures. This news alert may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Companies in emerging industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. *** This news alert is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. Global Markets News Network is a commercial digital brand compensated by the issuer (STKH) to provide coverage, sharing and syndication of news related to it and is thus subject to conflicts of interest. [ https://justpaste.it/bdh8v/pdf ]. Contact Details News Coverage globalmarkets.media@gmail.com

November 04, 2024 10:40 AM Eastern Standard Time

PathAI Launches PathExplore™ Fibrosis: An AI-Powered Pathology Breakthrough in Fibrosis, Collagen, and Fiber Quantification Directly from Whole Slide Images

PathAI

PathAI, a leader in AI-powered pathology solutions, is proud to introduce PathExplore™ Fibrosis 1 on our AISight® Translational Research platform, a one-of-a-kind AI tool designed to revolutionize fibrosis, collagen, and fiber quantification directly from whole-slide images (WSIs) of hematoxylin and eosin (H&E)-stained tissue. PathExplore™ Fibrosis offers an unprecedented ability to analyze morphology and spatial organization of fibrosis in the tumor microenvironment (TME) directly from routine pathology images at scale, providing new insights into tumor biology and therapeutic response. Fibrosis and collagen fibers are emerging as crucial biomarkers and drug targets due to their potential roles in cancer progression, metastasis, and immune response. Leveraging advanced machine learning techniques, PathExplore™ Fibrosis offers scalable, rapid analysis, making it a transformative tool in oncology translational research. PathAI’s solution facilitates this analysis directly from routine H&E pathology images from standard imaging platforms, democratizing access to key insights into tumor biology and therapeutic responses without the need of custom microscopy. "What began as internal research by our scientific team has evolved into a powerful tool for cancer researchers, enabling them to explore previously inaccessible aspects of tumor morphology," said Ben Glass, VP of Product and Translational Research at PathAI. "Fibrosis is increasingly recognized as a potentially important biomarker in cancer research. By making it possible to study this directly from routine H&E images, we’re providing researchers with the means to scale their understanding of disease biology, evaluate drug efficacy, and drive the development of new fibrosis-related therapies." “By combining the cell and tissue features provided by PathExplore™ 2 with collagen and fibrosis measurements from PathExplore™ Fibrosis, researchers now have access to an unprecedented multidimensional view of the TME,” said Eric Walk, M.D., FCAP, chief medical officer at PathAI. “From a single image, researchers can ask and answer new questions about the organization and morphology of fibrosis in the TME and how this inhibits or promotes cancer progression.” PathAI will be presenting novel findings utilizing PathExplore™ Fibrosis and the underlying technology at the upcoming Society of Immunotherapy of Cancer conference (SITC 2024) on November 6-11, 2024, in Houston, Texas. Be one of the first to access PathExplore™ Fibrosis by reaching out to us at bd@pathai.com or access our self-serve demo of PathExplore™ Fibrosis for hands-on experience here. SITC 2024 Abstracts #1378: Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer - in collaboration with Incendia Therapeutics #88: Machine learning-based collagen fiber quantification enables analysis of the pancreatic cancer tumor microenvironment directly from hematoxylin and eosin-stained whole slide images Footnotes 1: PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures. 2: PathExplore™ is for research use only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 04, 2024 10:00 AM Eastern Standard Time

ETFs: A Streamlined Approach to Sector-Specific Investment

Select Sector SPDR

In the dynamic world of financial markets, the Select Sector SPDR ETFs offer a practical method for investors seeking sector-specific investments. By segmenting the S&P 500 into defined sectors, these ETFs present both individual and institutional investors with an opportunity to build more targeted and strategic investment portfolios. Select Sector SPDR ETFs are designed to cater to various segments of the economy, allowing investors to concentrate their investments based on specific economic sectors, aligned with their investment goals, risk tolerance, and market perspectives. Overview of the available Select Sector SPDR ETFs Communication Services Select Sector SPDR Fund (XLC) is centered around telecommunications and media companies. Consumer Discretionary Select Sector SPDR Fund (XLY) is comprised of companies involved in non-essential goods and services focused on luxury items, automobiles, and hotels. Consumer Staples Select Sector SPDR Fund (XLP) is primarily essential consumer goods and services like beverages, clothing, and personal products. Energy Select Sector SPDR Fund (XLE) is focused on the energy sector which includes oil and natural gas industries. Financials Select Sector SPDR Fund (XLF) includes banking, capital markets, and insurance industries. Health Care Select Sector SPDR Fund (XLV) is dedicated to pharmaceuticals, healthcare equipment, and biotechnology. Industrials Select Sector SPDR Fund (XLI) encompasses manufacturing, construction, and aerospace companies. Materials Select Sector SPDR Fund (XLB) focuses on mining, construction materials, and packaging sectors. Real Estate Select Sector SPDR Fund (XLRE) looks into commercial real estate services and Real Estate Investment Trusts (REITs), excluding Mortgage REITs. Technology Select Sector SPDR Fund (XLK) is focused on the information technology, semiconductor, and electronics industries. Utilities Select Sector SPDR Fund (XLU) centers around electricity and natural gas companies. The Select Sector SPDR ETFs provide an uncomplicated and transparent way to navigate sector-specific investments, allowing investors to adjust their strategies in response to ever-changing market dynamics. This sector-focused approach can provide detailed analysis and strategic portfolio management, offering a valuable tool for investors to fine-tune their investment allocations. As the ETF landscape continues to evolve, the Select Sector SPDR provides a mechanism for investors aiming to fine tune their investment strategies through focused sector allocations. This structured investment avenue supports the development of robust and adaptive portfolios, tailored to meet diverse investor needs and market conditions. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007907 EXP 12/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

November 01, 2024 05:00 AM Eastern Daylight Time

VIZIA Diagnostics Selects PathAI and the AISight Image Management System to Support the Transition to Digital and AI-Powered Pathology

PathAI

PathAI, a leader in digital and AI-powered pathology solutions, and VIZIA Diagnostics, a GI- specialized pathology laboratory based in Alpharetta, Georgia, have announced that VIZIA has adopted PathAI’s AISight Ⓡ1 Image Management System (IMS) and AI technology to advance the precision and operational efficiency of its pathology services. In today’s rapidly evolving pathology landscape, independent labs face increasing pressure to provide timely and accurate assessments. To meet these demands, VIZIA Diagnostics conducted a thorough evaluation of digital pathology solutions and selected PathAI’s AISight Image Management System as the ideal platform. AISight’s robust workflow optimization, advanced case management, and broad applicability across various use cases were key factors in the decision. By integrating AISight with algorithm products, VIZIA Diagnostics aims to improve turnaround times for their clients and deliver even higher-quality pathology services. "AISight offers more than just efficiency; it empowers us to lead in the evolving field of gastrointestinal pathology," said Gregg Costantino, CEO of VIZIA Diagnostics. "By streamlining our workflows and enhancing accuracy, we're able to deliver faster, more precise results for our clients. This collaboration aligns with our commitment to being a flexible and quality-focused partner, providing exceptional service and care in the GI space, and positioning us at the forefront of digital and AI pathology." "The transformative potential of AI and Digital Pathology, coupled with the growing need for business-critical solutions our pathologists and GI providers require, was at the forefront of our decision to adopt this system," added Ed Cochrane, commercial director of VIZIA Diagnostics. “PathAI’s platform provides us unmatched agility and responsiveness for the dynamic landscape of anatomic pathology and our diverse customer base”. "The selection of PathAI by VIZIA Diagnostics reflects our shared commitment to improving patient outcomes through innovative, digital, and AI-powered pathology solutions," said Andy Beck, MD, PhD, co-founder and CEO of PathAI. "By adopting these technologies, VIZIA Diagnostics is well-positioned to meet the growing demand for more efficient, high-quality pathology operations. We are excited to support them as they embark on their digital journey to transform their pathology services." AISight is a cloud-native, intelligent enterprise workflow solution trusted by pathologists worldwide. As a centralized platform for case management, workload balancing, and image management, AISight seamlessly integrates best-in-class artificial intelligence tools from PathAI and third-party partners. This comprehensive approach will enable VIZIA Diagnostics to address a broad spectrum of histopathology use cases efficiently and consistently. Footnote 1. AISight is for Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com. About VIZIA Diagnostics VIZIA Diagnostics is an established leader in gastrointestinal pathology, dedicated to advancing diagnostic services through enhanced processes and exceptional patient care. As a vital partner in healthcare, VIZIA leverages advanced, modern technology and the expertise of its dedicated team to deliver accurate, timely, and reliable results. Focused on setting new industry standards, VIZIA's experts ensure that these advanced solutions elevate the quality of GI diagnostics and improve patient outcomes. For more information on VIZIA Diagnostics, please visit www.viziadx.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2024 10:00 AM Eastern Daylight Time

Avenue Z Launches New Public Affairs Practice to Help Clients Navigate Complexities of Modern Advocacy

Avenue Z

Avenue Z, a media and technology company, today announced the launch of its Public Affairs Group, a multidisciplinary, strategic practice designed to shape client outcomes in public and private advocacy, shareholder activism and ESG, philanthropy and civil society, and regulatory environments. In response to the growing power and control from big media companies and tech companies, Avenue Z’s new Public Affairs Group leverages a blend of communications, media, creative, and technology to affect meaningful change. The company’s approach supports clients to achieve consensus and desired outcomes by connecting highly targeted content to the right audiences at the right time, building trust. “The way the public is gaining information and forming perspectives has changed, and organizations need to engage their audiences across all channels in new ways,” said Nneka Etoniru, Avenue Z’s EVP of Global Brand Strategy and lead of the new Public Affairs Group. “Our solutions are uniquely positioned to help clients achieve lasting influence by guiding them through critical moments, enhancing their public image, and accomplishing their goals.” “Making a quantifiable impact in public affairs, akin to brand marketing or reputation management, requires both human and technology-informed approach,” said Jeffrey Herzog, Avenue Z founder and CEO. “Our strength lies in blending storytelling, media, and data to create influential connections across channels - from the Wall Street Journal to TikTok." Avenue Z’s Public Affairs practice is tailored to serve a diverse range of clients, including: Private Sector: Helping corporations gain consensus among decision-makers and standard bearers, secure contracts and public-private partnerships, and win necessary approval. Public Sector: Assisting municipal, state, and federal agencies with raising awareness, launching public health initiatives, combatting electoral misinformation, and developing educational campaigns across demographics. High-Profile Public Figures: Assisting in navigating public opinion, counter-influencing harassment campaigns, managing crises, and curating strategically engaging online conversations to protect their reputation. Charities and Philanthropies: Supporting non-profits in raising funds, advancing agendas, enhancing prestige, and navigating challenges to maximize organizational impact. Trade Organizations and Industry Groups: Helping industry-specific organizations advocate for their members' interests, inform external audiences on policy impact, and shape public perception of their industry. Along with the practice launch, Avenue Z has released an insightful trends report, offering a deep dive into the latest shifts shaping public policy and communication, helping organizations stay ahead of the curve. Public Affairs Trend Report 2024: Shaping Perception and Driving Outcomes in High-Stakes Environments covers trends impacting key sectors from healthcare to fintech, venture capital, emerging tech, manufacturing, and more. Read the full report, here. Avenue Z’s ability to lead high-stakes special situations is built on a foundation of expertise lasting more than 25 years. The company’s heritage dates back to 1998, when digital visionary and entrepreneur Jeffrey Herzog pioneered search engine marketing and later, sold iCrossing, his first digital media company, to Hearst Magazines for $450 million. Avenue Z is a media and technology company breaking traditional boundaries between marketing, advertising and PR to increase client revenue and elevate their reputation. From the Wall Street Journal to TikTok, PR to social and search, we create narratives that drive commerce, connections, and conversion, across all channels. With experts, tech and teams based in New York, Orlando, Miami and global reach - we drive influence. Visit www.avenuez.com Contact Details Avenue Z Rachael Zahn +1 407-637-2833 press@avenuez.com Company Website https://www.avenuez.com/

October 30, 2024 07:48 AM Eastern Daylight Time

News Release

NuggMD is Providing Free Medical Cannabis Evaluations to Veterans on Veterans Day

NuggMD

NuggMD, the nation's leading telemedicine platform for cannabis, today announced that it is providing free online medical marijuana evaluations to veterans from Nov. 7 to Nov. 11. Rates of PTSD range from 10% to 30% among war-time vets and 31% struggle with chronic pain. Additionally, according to the U.S. Department of Veterans Affairs, fewer than 50% of veterans in need of mental health treatment end up receiving it. While cannabis remains illegal federally, 38 states and several U.S. territories have legalized cannabis used to treat qualifying medical conditions, among them PTSD and chronic pain. “Every adult deserves the freedom to use cannabis. That is what we stand for,” said Bobby Brock, vice president of marketing at NuggMD. “We urge our peers in the cannabis industry to use their resources to help veterans, because serving in the armed forces is one of the most selfless, patriotic things an American can do. We also invite policymakers to take seriously the potential that cannabis may have to improve the quality of life of those who choose to enlist, both as they serve and after they return home.” The free evaluations will be offered to all veterans who reside in the 28 markets that NuggMD serves, and who provide valid proof of service and their state-issued identification. The applicable states are listed on NuggMD’s website, and veterans can secure their appointment using NuggMD’s on-demand platform from 8 AM to 10 PM in their local time zone. In addition to providing free evaluations to veterans, the company is also offering a 25% discount to the spouses of veterans, under the same conditions. Since its launch in 2016, NuggMD's affiliated medical cannabis practitioners have helped over two million patients connect with qualified medical cannabis doctors. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 2,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

October 29, 2024 02:50 PM Eastern Daylight Time

AGC Biologics Appoints Alberto Santagostino as new Chief Executive Officer

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Alberto Santagostino to Chief Executive Officer and President of AGC Biologics, effective November 1 st. Alberto has had a distinguished career in biotech, pharma and managing large-scale global CDMO operations. His expertise and knowledge will lead AGC Biologics’ next chapter as the company reemphasizes delivering reliable services to biopharmaceutical developers without unnecessary complications. AGC Biologics will have a friendly business approach with customers and provide them with expert CDMO services to become an increasingly preferred service provider. AGC Biologics intends to be valued as collaborative, reliable and stable: it will be a safe harbor for those customers seeking to minimize geopolitical risks, intellectual property concerns, steep price expectations and transactional or confrontational supplier relationships. This direction builds on the company’s 30 years of biopharma CDMO experience, including serving more than 250 customers across over 400 different projects, with more than 90 successful regulatory inspections and 25 commercial products launched. Alberto joins AGC Biologics after most recently serving as the Head of Cell and Gene Technology (CGT) at Lonza for six years. While there, his business unit grew four-fold in size by enabling clients to advance four new CGT therapies to commercial production and many more to late-stage clinical milestones, with now thousands of patients being cured annually. During his tenure, Alberto led the industrialization of CGT therapeutics manufacturing: from a “science workshop” into “industrial scale compliant operations” with several positive Pre-Approval Inspections (PAI) from the U.S. FDA and EMA that led to three CGT biomanufacturing sites becoming licensed for commercial supply. Before Lonza, Alberto was a Partner in the Pharmaceutical & Medical Product practice at McKinsey & Co., serving more than 70 clients with over 200 projects. While there, Alberto developed a proprietary operational benchmark that analyzed the performance of more than 30 biomanufacturing sites and published books and articles about Biopharma operations. Alberto currently serves as a board member for the Alliance for Regenerative Medicine (ARM) and holds a degree in Industrial Biotechnology from the University of Milano-Bicocca and a Master of Business Administration from Politecnico di Milano. “I am excited to announce Alberto is joining us to lead AGC Biologics and to set the tone for the coming years. We share the common vision of service, delivery and quality that is at the core of AGC Group’s business philosophy,” said Murano Tadashi, President of AGC Life Science Company. “I am confident Alberto will bring both a wide knowledge of the biopharma industry and the experience of successfully leading growth at scale. He will enhance AGC Biologics’ reputation as an increasingly preferable CDMO in the industry.” “I am grateful for the opportunity to serve AGC Biologics and its team members and customers. We will have customers at the heart of our action and our technical talent as the enabler of our CDMO’s aspiration of friendly & expert services to the biopharma industry,” said Alberto Santagostino, new Chief Executive Officer at AGC Biologics. “Over the last several years our industry has faced more complexity. Chemistry Manufacturing Control (CMC), technical development and manufacturing have been a headache for the biopharma industry, also, and sometimes especially, when dealing with CDMOs. AGC Biologics aspires to become an easy choice. We will be a friendly CDMO to work with, expert and reliable in our technical role. We will leverage our technical talent, established centers of excellence, commercial track record, growing capacity at our global sites and the solidity of the parent company, to offer reliability while staying uncomplicated to work with. Ultimately, ‘#YourfriendlyCDMOexpert.’ ” For more information on AGC Biologics’ end-to-end global CDMO services in the U.S., Europe and Japan visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

October 28, 2024 06:03 AM Eastern Daylight Time

PathAI Unveils New Features on AISight Image Management System: Introducing Guided Algorithm Review and Z-Stack Image Support

PathAI

PathAI, a global leader in AI-powered digital pathology, today announced the launch of two new features on its AISight® 1 Image Management System (IMS): Guided Algorithm Review and Z-Stack Image Support. These enhancements reflect PathAI’s ongoing commitment to empowering pathologists with innovative tools that enhance pathology interpretation, optimize laboratory operations, and lay the foundation for broader adoption of AI tools in the field of pathology. The Guided Algorithm Review feature is designed to help pathologists streamline and enhance case evaluations by highlighting potential Fields of Interest (FOIs) identified by algorithms. TumorDetect 2, PathAI’s AI product, will be the first to incorporate this functionality, highlighting key areas of interest. By automatically pinpointing these critical areas, the feature allows pathologists to focus their initial review on the regions that require the most attention. Key Features of the Guided Algorithm Review: Gallery of FOIs: A visual gallery of algorithm-detected fields of interest provides an intuitive way for pathologists to navigate to key tissue areas requiring further analysis. Click-Through Review: Enables systematic, step-by-step navigation through regions highlighted by the AI’s predictions, such as areas with high tumor concentration or biomarker quantification, potentially streamlining the review process and enhancing thoroughness. Enhanced Interpretability: Overlays and side-by-side comparisons improve the clarity of AI predictions, allowing pathologists to better interpret and verify the results. Third-Party AI Integration: Allows for seamless integration with third-party AI algorithms, enabling pathologists to work with various AI solutions in a unified platform, enhancing flexibility and adaptability across different AI tools and workflows. In addition to the Guided Algorithm Review, PathAI’s Z-Stack Image Support introduces a multi-layer imaging capability that enables pathologists to examine all layers of a multi-layered Whole Slide Image (WSI), producing a 3D-like representation of slides. This feature is particularly beneficial in cytology, where three-dimensional cell clusters often require a more nuanced, layered analysis. Key Benefits of the Z-Stack Image Support: Multi-Layer Viewing: Pathologists can view all layers of a multi-layered Whole Slide Image (WSI), providing an experience similar to a microscope fine focus, particularly useful for cytology cases. Efficient Navigation: Features such as Focus Control and keyboard shortcuts allow for smooth transitions between image layers. Customizable Workflow: Pathologists can personalize their review process with adjustable zoom, pan, and annotation features, and track their progress through visual indicators. PathAI has also upgraded its ArtifactDetect 3 algorithm, broadening its support for additional file types, such as.mrxs format files and stains, including Masson’s Trichrome and other special stains. These improvements allow laboratories to apply quality control measures across a wider range of specimens and staining protocols, further optimizing laboratory efficiency. Additional AISight Enhancements: Refreshed User Interface: Includes categorized tables for clearer quantitative results, such as tissue areas and cell counts, facilitating easier interpretation. Custom Slide Panning: Enhanced control features like Snap to Zoom and adjustable animation durations for more precise slide navigation. Automatic Specimen Orientation: Automatically rotates skin specimens based on metadata, ensuring consistency and accuracy in evaluations. “We are thrilled to introduce these new capabilities to the AISight IMS platform,” said Eric Walk, M.D., FCAP, chief medical officer at PathAI. “The Guided Algorithm Review and Z-Stack Image Support are significant advancements that help pathologists conduct high-quality assessments with efficiency and precision. These tools help enhance and streamline case management supporting the needs of modern pathology labs.” Footnotes AISight is for research use only in the US and is not for use in diagnostic procedures. TumorDetect is a workflow optimization algorithm available on AISight for research use only. ArtifactDetect is a quality control algorithm available on AISight for research use only. About PathAI PathAI is a global leader in AI-powered digital pathology solutions, dedicated to advancing diagnostic accuracy and operational efficiency in pathology laboratories worldwide. Through the integration of cutting-edge technology and strategic partnerships, PathAI empowers pathologists to be leaders in precision pathology and shape the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 23, 2024 10:00 AM Eastern Daylight Time

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market

Benzinga

By Kyle Anthony, Benzinga NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases – such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease – recently announced its plans to file for early commercialization approval for PrimeC, the firm’s leading drug candidate designed to synergistically target several biological mechanisms of ALS, under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy. This submission is backed by promising results from the company’s phase 2b ALS PARADIGM clinical trial and supplementary clinical and preclinical data. ALS Explained ALS is a nervous system disease that affects nerve cells in the brain and spinal cord. The disease causes loss of muscle control, and gradually worsens over time. Often called Lou Gehrig's disease after the baseball player who was diagnosed with it, the exact cause of the disease is still not known. ALS often begins with muscle twitching and weakness in the arm or leg, trouble swallowing or slurred speech. Eventually, ALS affects the control of the muscles needed to move, speak, eat and breathe. There is no cure for this fatal disease. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and European Union. The Efficacy Of NeuroSense’s PrimeC Treatment PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation with a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several biological mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (RNA) regulation. The goal is to inhibit the progression of ALS. NeuroSense reports that PARADIGM, a prospective, multinational, randomized, double-blind, placebo-controlled phase 2b clinical trial of PrimeC in ALS, has demonstrated the drug's efficacy. The trial d emonstrated that PrimeC significantly reduced disease progression (p=0.009) and improved survival rates by 43% compared to placebo, highlighting its potential as a breakthrough therapy for ALS. The trial included 68 participants living with ALS in Canada, Italy and Israel. 96% of the trial participants who completed the 6-month double-blind portion of the trial chose to receive treatment with PrimeC through a 12-month open-label extension. As of June 2024, all participants who completed the 18-month trial treatment duration requested to continue PrimeC, which is provided to them in an Investigator Initiated Trial, not limited to time. The PARADIGM clinical study observed a statistically significant slowing of disease progression in patients who used PrimeC versus placebo, based on the ALS Functional Rating Scale-Revised (ALSFRS-R). The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) is the gold standard instrument for evaluating the functional status of patients with ALS. It is used to monitor functional change in a patient over time. NeuroSense reports that most patients enrolled in both the active and placebo arms of the trial were concurrently treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease progression well beyond the level afforded by the FDA-approved ALS drug. The FDA and the European Medicines Agency have granted PrimeC Orphan Drug Designation. Commercialization Of PrimeC In Canada And Worldwide Health Canada’s Notice of Compliance with Conditions (NOC/c) is authorization to market a drug, with the condition that the sponsor undertake additional studies to verify the clinical benefit. As such, this speeds up the time to market for the drug, enabling earlier commercialization. In advancing PrimeC's commercialization potential, NeuroSense plans to submit its regulatory dossier to Health Canada in Q2 2025, with a regulatory decision anticipated by Q1 2026, and NeuroSense estimates the market opportunity for PrimeC in Canada alone to be approximately $100 million to $150 million in annual revenue, reflecting the unmet need for effective ALS treatments. Beyond Canada, NeuroSense plans to pursue regulatory approval in additional global markets as part of its broader strategy to make PrimeC accessible to ALS patients worldwide. Alon Ben-Noon, CEO of NeuroSense, stated, “The Canadian market presents a significant near-term opportunity, with the addressable market for PrimeC valued above $100 million in annual revenue. Securing early commercialization approval in Canada would represent an important milestone, not only to address the unmet need for ALS treatments but also as part of our strategy to drive sustainable growth. With additional markets on our radar, this marks the beginning of what we anticipate will be a long-term revenue-generating opportunity." Looking Forward NeuroSense’s PrimeC has the potential to reshape the landscape for ALS treatment, enhancing the quality of life for individuals around the globe afflicted by this debilitating disease. The promising results from the PARADIGM clinical trial and NeuroSense's commercial advancement plans for the drug indicate that PrimeC may soon be able to benefit ALS patients around the world and potentially position the company to be a leader in treating the disease. Featured photo courtesy of NeuroSense Therapeutics. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 17, 2024 02:00 PM Eastern Daylight Time

Image

1 2 3 4 5 ... 247

Back